Jason Broderick on Muck Rack

Jason Broderick

Verified
Cranbury
As seen in: Targeted Oncology, EIN News, NewsBreak, HCP Live, Contagion Live, American Journal of Managed Care, Pharmacy Times, ONCOLOGY journal, CURE Magazine, OncLive, Diagnostic Imaging and
Associate Director, Digital Editorial @OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

VIKTORIA-1 Regimen Shows Efficacy in PIK3CA+ Breast Cancer

|
By Sabrina Serani , Jason Broderick , Russ Conroy
| ONCOLOGY journal
Combining gedatolisib with fulvestrant (Faslodex) with or without palbociclib (Ibrance) significantly improved outcomes vs single-target standard therapy among those with hormone receptor (HR)–positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to a presentation on findings from the phase 3 VIKTORIA-1 study (NCT05501886) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.1 The findings, presented by Sara A.
Open in Who Shared View Duplicates (2) Issue with article?

Pembrolizumab/Vaccine Combo Improves RFS in High-Risk Resected Melanoma

|
By Andrea Eleazar, Sabrina Serani , Jason Broderick 
| ONCOLOGY journal
Meaningful improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were observed with a mRNA-based cancer vaccine, intismeran autogene, plus pembrolizumab (Keytruda) among patients with high-risk resected melanoma, according to a presentation at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO) on 5-year follow-up data from the phase 2 KEYNOTE-942 trial (NCT03897881).1 With a median planned follow-up of 60.3 months (range, 50.5-76.4...
Open in Who Shared View Duplicates (2) Issue with article?

EMERALD-3 Trial Shows Improved PFS in Unresectable Liver Cancer

|
By Jason Broderick , Sabrina Serani , Nathan Goodyear
| ONCOLOGY journal
Patients with with unresectable embolization-eligible hepatocellular carcinoma (eeHCC) experienced significant improvements in progression-free survival (PFS) with the STRIDE regimen of durvalumab (Imfinzi) plus tremelimumab (Imjudo) and transarterial chemoembolization (TACE) with or without lenvatinib (Lenvima) vs TACE alone, according to a presentation on data from the phase 3 EMERALD-3 trial (NCT05301842) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.1-3 The...
Open in Who Shared View Duplicates (2) Issue with article?
See all 350 licensed articles (1,476 Total)

Actions

Share this page

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified